• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. What We Can Expect From Second-Quarter Earnings

    Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.

  2. Sanofi Shakes Off Patent Losses

    The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

  3. Finding a Margin of Safety in a Fully Valued Market

    These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

  4. 6 Key Concepts to Stock Investing Defined

    From moats to fair value to stewardship, we explain the key pillars of our approach to equities.

  5. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  6. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  7. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

  8. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

  9. Novo's Scale Advantages and Drug Lineup Broaden Its Wide Moat

    Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.

  10. Ideas From the Wide Moat Focus Index

    Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.

123

©2017 Morningstar Advisor. All right reserved.